Quick Answer
FibroBiologics, Inc. reported R&D Expense of $7.41 million for fiscal year 2025.
FibroBiologics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $7.41M | +64.5% |
| 2024 | $4.50M | +90.2% |
| 2023 | $2.37M | +106.5% |
| 2022 | $1.15M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.79M | +129.9% | +36.6% |
| June 30, 2025 | $2.04M | +109.3% | +14.7% |
| March 31, 2025 | $1.78M | +85.4% | +46.7% |
| September 30, 2024 | $1.21M | +112.4% | +24.4% |
| June 30, 2024 | $975.0K | +78.2% | +1.6% |
| March 31, 2024 | $960.0K | +100.8% | +68.1% |
| September 30, 2023 | $571.0K | — | +4.4% |
| June 30, 2023 | $547.0K | — | +14.4% |
- FibroBiologics, Inc. showed an increase of +64.5% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, FibroBiologics, Inc.’s r&d expense has grown by 545.8% (from $1.15 million to $7.41 million).
- The most recent figure is from FibroBiologics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: